<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35907815</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Neurocognitive screening in patients following SARS-CoV-2 infection: tools for triage.</ArticleTitle><Pagination><StartPage>285</StartPage><MedlinePgn>285</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">285</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-022-02817-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognitive complaints are common in patients recovering from Coronavirus Disease 2019 (COVID-19), yet their etiology is often unclear. We assess factors that contribute to cognitive impairment in ambulatory versus hospitalized patients during the sub-acute stage of recovery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this cross-sectional study, participants were prospectively recruited from a hospital-wide registry. All patients tested positive for SARS-CoV-2 infection using a real-time reverse transcriptase polymerase-chain-reaction assay. Patients&#x2009;&#x2264;&#x2009;18&#xa0;years-of-age and those with a pre-existing major neurocognitive disorder were excluded. Participants completed an extensive neuropsychological questionnaire and a computerized cognitive screen via remote telemedicine platform. Rates of subjective and objective neuropsychological impairment were compared between the ambulatory and hospitalized groups. Factors associated with impairment were explored separately within each group.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 102 patients (76 ambulatory, 26 hospitalized) completed the symptom inventory and neurocognitive tests 24&#x2009;&#xb1;&#x2009;22&#xa0;days following laboratory confirmation of SARS-CoV-2 infection. Hospitalized and ambulatory patients self-reported high rates of cognitive impairment (27-40%), without differences between the groups. However, hospitalized patients showed higher rates of objective impairment in visual memory (30% vs. 4%; p&#x2009;=&#x2009;0.001) and psychomotor speed (41% vs. 15%; p&#x2009;=&#x2009;0.008). Objective cognitive test performance was associated with anxiety, depression, fatigue, and pain in the ambulatory but not the hospitalized group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Focal cognitive deficits are more common in hospitalized than ambulatory patients. Cognitive performance is associated with neuropsychiatric symptoms in ambulatory but not hospitalized patients. Objective neurocognitive measures can provide essential information to inform neurologic triage and should be included as endpoints in clinical trials.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blackmon</LastName><ForeName>Karen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-2665-7807</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. blackmon.karen@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powers</LastName><ForeName>Harry Ross</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>Wendelyn</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhakaran</LastName><ForeName>Divya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Individualized Medicine, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woolston</LastName><ForeName>Dixie</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedraza</LastName><ForeName>Otto</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Res Sq. 2022 Feb 07:rs.3.rs-1127420. doi: 10.21203/rs.3.rs-1127420/v1</RefSource><PMID Version="1">35169789</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014218" MajorTopicYN="N">Triage</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Memory</Keyword><Keyword MajorTopicYN="N">Myalgic encephalomyelitis</Keyword><Keyword MajorTopicYN="N">Neuroinfectious disease</Keyword><Keyword MajorTopicYN="N">Neuropsychology</Keyword><Keyword MajorTopicYN="N">Post intensive care unit syndrome</Keyword></KeywordList><CoiStatement>GSD owns stock (&gt;&#x2009;$10,000) in ANI Pharmaceuticals (a generic pharmaceutical company). He serves as a topic editor for DynaMed (EBSCO), overseeing development of evidence-based educational content, a consultant for Parabon Nanolabs (advice relevant to NIH small business grant submission), and as the Clinical Director of the Anti-NMDA Receptor Encephalitis Foundation, Inc, Canada (uncompensated). None of the other authors have conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>30</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35907815</ArticleId><ArticleId IdType="pmc">PMC9338515</ArticleId><ArticleId IdType="doi">10.1186/s12883-022-02817-9</ArticleId><ArticleId IdType="pii">10.1186/s12883-022-02817-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vanderlind WM, Rabinovitz BB, Miao IY, Oberlin LE, Bueno-Castellano C, Fridman C, et al. A systematic review of neuropsychological and psychiatric sequalae of COVID-19: implications for treatment. Curr Opin Psychiatry. 2021;34(4):420&#x2013;433. doi: 10.1097/YCO.0000000000000713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000713</ArticleId><ArticleId IdType="pmc">PMC8183238</ArticleId><ArticleId IdType="pubmed">34016818</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416&#x2013;427. doi: 10.1016/S2215-0366(21)00084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". Ann Clin Transl Neur. 2021;8(5):1073&#x2013;85. doi: 10.1002/acn3.51350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51350</ArticleId><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JP, Watson CJ, Badenoch J, Cross B, Butler M, Song J, et al. Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. J Neurol Neurosurg Psychiatry. 2021;92(9):932&#x2013;41. doi: 10.1136/jnnp-2021-326405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-326405</ArticleId><ArticleId IdType="pubmed">34083395</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles KH, McDonald M, Barron Y, Kennedy E, O'Connor M, Mikkelsen M. Surviving COVID-19 After Hospital Discharge: Symptom, Functional, and Adverse Outcomes of Home Health Recipients. Ann Intern Med. 2021;174(3):316&#x2013;325. doi: 10.7326/M20-5206.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5206</ArticleId><ArticleId IdType="pmc">PMC7707212</ArticleId><ArticleId IdType="pubmed">33226861</ArticleId></ArticleIdList></Reference><Reference><Citation>de Graaf MA, Antoni ML, ter Kuile M, Arbous M, Duinisveld A, Feltkamp M, et al. Short-term outpatient follow-up of COVID-19 patients: A multidisciplinary approach. EClinicalMedicine. 2021;32:100731. doi: 10.1016/j.eclinm.2021.100731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100731</ArticleId><ArticleId IdType="pmc">PMC7843037</ArticleId><ArticleId IdType="pubmed">33532720</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infection. 2020;81(6):E4&#x2013;E6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannan A, Mehedi HMH, Qayum MO, Akter F, Rob M, et al. A multi-centre, cross-sectional study on coronavirus disease 2019 in Bangladesh: clinical epidemiology and short-term outcomes in recovered individuals. New Microbes New Infect. 2021;40:100838. doi: 10.1016/j.nmni.2021.100838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmni.2021.100838</ArticleId><ArticleId IdType="pmc">PMC7834423</ArticleId><ArticleId IdType="pubmed">33520252</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. 2020;9:100163. doi: 10.1016/j.bbih.2020.100163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2020.100163</ArticleId><ArticleId IdType="pmc">PMC7581383</ArticleId><ArticleId IdType="pubmed">33111132</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YH, Wang YR, Wang Q, Chen Y, Chen X, Li Y, et al. Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. Mol Neurodegener. 2021;16(1):48. doi: 10.1186/s13024-021-00469-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00469-w</ArticleId><ArticleId IdType="pmc">PMC8287105</ArticleId><ArticleId IdType="pubmed">34281568</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L, Alfaro-Almagro F, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021;31:100683. doi: 10.1016/j.eclinm.2020.100683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100683</ArticleId><ArticleId IdType="pmc">PMC7808914</ArticleId><ArticleId IdType="pubmed">33490928</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldati AB, Almeida C, Lima M, Araujo A, Araujo-Leite MA, Silva MTT. Telephone Screening of Cognitive Status (TICS) in severe COVID-19 patients: Utility in the era of social isolation. eNurological Sci. 2021;22:100322. doi: 10.1016/j.ensci.2021.100322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2021.100322</ArticleId><ArticleId IdType="pmc">PMC7817447</ArticleId><ArticleId IdType="pubmed">33495738</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasoni D, Bai F, Castoldi R, Barbanotti D, Falcinella C, Mul&#xe8; G, et al. Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan. Italy J Med Virol. 2021;93(2):1175&#x2013;1179. doi: 10.1002/jmv.26459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26459</ArticleId><ArticleId IdType="pmc">PMC7461061</ArticleId><ArticleId IdType="pubmed">32841387</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo MS, Malsy J, P&#xf6;ttgen J, SeddiqZai S, Ufer F, Hadjilaou A, et al. Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2020;2(2):fcaa205. doi: 10.1093/braincomms/fcaa205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa205</ArticleId><ArticleId IdType="pmc">PMC7717144</ArticleId><ArticleId IdType="pubmed">33376990</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JH, Lin JJ, Doernberg M, Stone K, Navis A, Festa JR, et al. Assessment of Cognitive Function in Patients After COVID-19 Infection. JAMA Netw Open. 2021;4(10):e2130645. doi: 10.1001/jamanetworkopen.2021.30645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.30645</ArticleId><ArticleId IdType="pmc">PMC8536953</ArticleId><ArticleId IdType="pubmed">34677597</ArticleId></ArticleIdList></Reference><Reference><Citation>Halalau A, Imam Z, Karabon P, Karabon P, Mankuzhy N, Shaheen A, Tu J, et al. External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patients. Ann Med. 2021;53(1):78&#x2013;86. doi: 10.1080/07853890.2020.1828616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2020.1828616</ArticleId><ArticleId IdType="pmc">PMC7877986</ArticleId><ArticleId IdType="pubmed">32997542</ArticleId></ArticleIdList></Reference><Reference><Citation>van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626&#x2013;633. doi: 10.1097/MLR.0b013e31819432e5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e31819432e5</ArticleId><ArticleId IdType="pubmed">19433995</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Clinical management of COVID-19: living guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 (2021). Accessed 18 Nov 2021.</Citation></Reference><Reference><Citation>Gualtieri CT. An Internet-based symptom questionnaire that is reliable, valid, and available to psychiatrists, neurologists, and psychologists. MedGenMed. 2007;9(4):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234274</ArticleId><ArticleId IdType="pubmed">18311353</ArticleId></ArticleIdList></Reference><Reference><Citation>Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery. CNS Vital Signs. Arch Clin Neuropsych. 2006;21(7):623&#x2013;43. doi: 10.1016/j.acn.2006.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acn.2006.05.007</ArticleId><ArticleId IdType="pubmed">17014981</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS-Vital Signs. CNS Vital Signs Interpretation Guide White Paper. https://www.cnsvs.com/WhitePapers/CNSVS-BriefInterpretationGuide.pdf (2020). Accessed 18 Nov 2021.</Citation></Reference><Reference><Citation>Guilmette TJ, Sweet JJ, Hebben N, Koltai D, Mahone EM, Spiegler BJ, et al. American Academy of Clinical Neuropsychology consensus conference statement on uniform labeling of performance test scores. Clin Neuropsychol. 2020;34(3):437&#x2013;453. doi: 10.1080/13854046.2020.1722244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13854046.2020.1722244</ArticleId><ArticleId IdType="pubmed">32037942</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A practical and powerful approach to multiple testing. J Royal Stat Soc B. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Cabral CMN, Miyamoto GC, Franco KFM, Bosmans JE. Economic evaluations of educational, physical, and psychological treatments for fibromyalgia: a systematic review with meta-analysis. Pain. 2021;162(9):2331&#x2013;2345. doi: 10.1097/j.pain.0000000000002233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000002233</ArticleId><ArticleId IdType="pubmed">33605655</ArticleId></ArticleIdList></Reference><Reference><Citation>Wortman MSH, Lokkerbol J, van der Wouden JC, Visser B, van der Horst HE, Olde Hartman TC. Cost-effectiveness of interventions for medically unexplained symptoms: A systematic review. PLoS ONE. 2018;13(10):e0205278. doi: 10.1371/journal.pone.0205278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0205278</ArticleId><ArticleId IdType="pmc">PMC6188754</ArticleId><ArticleId IdType="pubmed">30321193</ArticleId></ArticleIdList></Reference><Reference><Citation>Dressing A, Bormann T, Blazhenets G, Schroeter N, Walter LI, Thurow J, et al. Neuropsychological profiles and cerebral glucose metabolism in neurocognitive Long COVID-syndrome. J Nucl Med. 2021 doi: 10.2967/jnumed.121.262677.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.262677</ArticleId><ArticleId IdType="pmc">PMC9258569</ArticleId><ArticleId IdType="pubmed">34649946</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez R, Balanza-Martinez V, Luperdi S, Estrada I, Latorre A, Gonz&#xe1;lez-Jim&#xe9;nez P, et al. Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med. 2021 doi: 10.1111/joim.13262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13262</ArticleId><ArticleId IdType="pmc">PMC8013333</ArticleId><ArticleId IdType="pubmed">33533521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou HT, Lu SJ, Chen J, Wei N, Wang D, Lyu H, et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. 2020;129:98&#x2013;102. doi: 10.1016/j.jpsychires.2020.06.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2020.06.022</ArticleId><ArticleId IdType="pmc">PMC7324344</ArticleId><ArticleId IdType="pubmed">32912598</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee NNM, Wilson FC, Curran DB, Lyttle N, McCann JP. Neurocognitive outcomes in adults following cerebral hypoxia: A systematic literature review. NeuroRehabilitation. 2020;47(2):83&#x2013;97. doi: 10.3233/NRE-203135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/NRE-203135</ArticleId><ArticleId IdType="pubmed">32716324</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandharipande PP, Girard TD, Jackson JC, Morandi A, Thompson J, Pun B, et al. Long-term cognitive impairment after critical illness. N Engl J Med. 2013;369(14):1306&#x2013;1316. doi: 10.1056/NEJMoa1301372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1301372</ArticleId><ArticleId IdType="pmc">PMC3922401</ArticleId><ArticleId IdType="pubmed">24088092</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur KT, Miller EH, Glendinning MD, Al-Dalahmah O, Banu MA, Boehme AK, et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain. 2021;144(9):2696&#x2013;2708. doi: 10.1093/brain/awab148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab148</ArticleId><ArticleId IdType="pmc">PMC8083258</ArticleId><ArticleId IdType="pubmed">33856027</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Xu J, Hou Y, Leverenz JB, Kallianpur A, Mehra R, et al. Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. Alzheimers Res Ther. 2021;13(1):110. doi: 10.1186/s13195-021-00850-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00850-3</ArticleId><ArticleId IdType="pmc">PMC8189279</ArticleId><ArticleId IdType="pubmed">34108016</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, Erben Y, Marquez CP, Jansen-West KR, Franco-Mesa C, Heckman MG, et al. Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19. Sci Transl Med. 2021;13(602). 10.1126/scitranslmed.abi7643</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8432951</ArticleId><ArticleId IdType="pubmed">34131052</ArticleId></ArticleIdList></Reference><Reference><Citation>Magusali N, Graham AC, Piers TM, Panichnantakul P, Yaman U, Shoai M, et al. A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene. Brain. 2021 doi: 10.1093/brain/awab337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab337</ArticleId><ArticleId IdType="pmc">PMC8500089</ArticleId><ArticleId IdType="pubmed">34619763</ArticleId></ArticleIdList></Reference><Reference><Citation>Munshi MN. Cognitive Dysfunction in Older Adults With Diabetes: What a Clinician Needs to Know. Diabetes Care. 2017;40(4):461&#x2013;467. doi: 10.2337/dc16-1229.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc16-1229</ArticleId><ArticleId IdType="pubmed">28325796</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira MM, Passos VMA, Barreto SM, Schmidt MI, Duncan BB, Beleigoli AMR, et al. Association between diabetes and cognitive function at baseline in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) Sci Rep. 2020;10:1596. doi: 10.1038/s41598-020-58332-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-58332-9</ArticleId><ArticleId IdType="pmc">PMC6994611</ArticleId><ArticleId IdType="pubmed">32005901</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce BK, Allman ME, Rivera FA, Wang B, Berianu F, Butendieck RR, et al. Intensive Multicomponent Fibromyalgia Treatment: A Translational Study to Evaluate Effectiveness in Routine Care Delivery. J Clin Rheumatol. 2020 doi: 10.1097/RHU.0000000000001555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000001555</ArticleId><ArticleId IdType="pubmed">32897994</ArticleId></ArticleIdList></Reference><Reference><Citation>Cysique LA, Lojek E, Cheung TC, Cullen B, Egbert AR, Evans J, et al. Assessment of Neurocognitive Functions, Olfaction, Taste, Mental, and Psychosocial Health in COVID-19 in Adults: Recommendations for Harmonization of Research and Implications for Clinical Practice. J Int Neuropsychol Soc. 2021;1&#x2013;19. 10.1017/S1355617721000862</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825876</ArticleId><ArticleId IdType="pubmed">34365990</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>